+

WO1993025209A1 - Compositions pour le traitement et la prophylaxie d'inflammations et de dermatoses induites par des virus, et procede pour leur preparation - Google Patents

Compositions pour le traitement et la prophylaxie d'inflammations et de dermatoses induites par des virus, et procede pour leur preparation Download PDF

Info

Publication number
WO1993025209A1
WO1993025209A1 PCT/HU1993/000038 HU9300038W WO9325209A1 WO 1993025209 A1 WO1993025209 A1 WO 1993025209A1 HU 9300038 W HU9300038 W HU 9300038W WO 9325209 A1 WO9325209 A1 WO 9325209A1
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
inflammations
preparation
prophylaxis
treatment
Prior art date
Application number
PCT/HU1993/000038
Other languages
English (en)
Inventor
György Hangay
András Kelen
Péter KESERU^'
Vodnár János DEMETER
Éva FRIEDMAN
Éva ALBERTI
György KOVÁCS
Pál Putz
Izabella Kardics
Józsefné MÉSZÁROS
Original Assignee
Fabulon Rg Kozmetikai Kft.
MÉSÁROS, József
ERDÉLYINE MÉSZÁROS, Krisztina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabulon Rg Kozmetikai Kft., MÉSÁROS, József, ERDÉLYINE MÉSZÁROS, Krisztina filed Critical Fabulon Rg Kozmetikai Kft.
Priority to AU43525/93A priority Critical patent/AU4352593A/en
Publication of WO1993025209A1 publication Critical patent/WO1993025209A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the invention relates to new cosmetic and/or medicinal compositions which beneficially affect virus-induced infections and inflammations- of the skin and mucosa and promote the regeneration of the dermatoses caused, i.e. the compositions are able to restore the initial conditions of the skin.
  • compositions of the invention are special ⁇ ly suitable for the treatment of infections and dermatoses induced by herpes virus.
  • the cited patents also confirm that in this field of indication the use of natural substances is becoming popular world-wide, too.
  • the present invention is also a representative of this trend of development, and is based on the observation that active ingredient concentrates can be prepared from particular natural substances by a specific process which can be used, alone or in combination, for the production of cosmetic agents or medicinal cosmetics of improved activity. Their activity can be further increased by applying adjuvants or specific formulations.
  • the invention relates to compositions of manifold application with viricide, antiinflamma- tory and regenerating activity wherein the concentrations of the ingredients given % by weight are as follows: Glycyrrhizin, preferably in the form of sweet-root extract 0.005-0.4
  • Rosemary acid preferably in the form of plant extract 0.005-0.4
  • compositions may contain further carriers, additives and auxiliary materials usually applied in the preparation of cosmetic or medicinal compositions, preferably water, propyleneglycol, acrylamide-sodium aerylate copolymer, PEG-7, glycerol cocoate and isooctyl nonanoate, as well as solubilizing agents, lipids, preservatives and fragrance components in hydrogel, lotion-ointment, liquid emulsion, spray, stick or drop formulation.
  • auxiliary materials usually applied in the preparation of cosmetic or medicinal compositions, preferably water, propyleneglycol, acrylamide-sodium aerylate copolymer, PEG-7, glycerol cocoate and isooctyl nonanoate, as well as solubilizing agents, lipids, preservatives and fragrance components in hydrogel, lotion-ointment, liquid emulsion, spray, stick or drop formulation.
  • rosemary acid (caffeoyl- -hydroxy-dihydrocaffeic acid) , together with quinic acid, chlorogenic acid and caffeic acid, is present in plants of the labiate family (Laminaceae) , mainly in Melissa officinalis, Hyssopus officinalis, Rosmarinus officinalis and Salvia officinalis. Its virostatic, antibacterial and antimycotic potency is reported by I. K. Heimann and . Schultze in the Zeitschrift fur Phythotherapie Sept. 1988, 82-83.
  • sweet root (Glycyr- rhiza glabra) extracts are used as sweeteners to improve taste and as expectorants (B. Issekutz: (Drug pres ⁇ cription, Gy ⁇ gyszerrendeles p. 600 Medicina, Budapest, 1979) .
  • the regular use of standard preparations may reduce the increased tension of the stomach wall and the inflamination of gastric mucosa (Gizella Verzar Petri: Gy ⁇ gyn ⁇ venyek a gy ⁇ gyaszatban (Medicinal plants in therapy), p. 92, Medicina, Budapest, 1984).
  • Russian authors [I. A.
  • Glycyr- rhizin the major constituent of sweet root has mineralo- corticoid, antiinflammatory, antiedema and epithelizing (wound healing) properties.
  • the volatile oil of thyme (Thymus vulgaris) contains mainly thymol, carvacrol, p-cymol, furthermore linalool, borneol, geraniol and ⁇ - pinene.
  • thyme oil Due to its thymol content the thyme oil has viricide effect and inhibits a major part of wound bacteria even at 3000fold dilution (Gizella Verzar Petri: Medicinal plants in therapy, Medicina, Budapest, 1984, p. 74.).
  • the ⁇ -bisabolol is one of the major components of camomile (Matricaria chamomilla) . Primarily it has antiinflam atory effect and promotes granulation. The allantoin promotes the skin-regeneration and hydration.
  • the collagens which can be found in the skin, also play role in hydration, but based on other mechanism.
  • the polydocanol is ingredient of numerous medicinal and cosmetic composition. It has analgetic and local anaesthetic effect.
  • An aqeous alcohol (methanol, ethanol, iso- propanol) extract is prepared from the leaves of a plant from Laminaceae family, e.g. rosemary, melilot (Melissa officinalis) , Salvia officinalis and Hyssopus officinalis, etc. After removing the sol ⁇ vent the residue is acidified to pH 2-3 with an inorganic acid, the mixture is extracted with a water immiscible solvent (ether, chloroform, di- chloromethane, ethyl acetate, etc.), the layers are separated and the solvent is removed from the orga ⁇ nic layer yielding a dry extract.
  • a water immiscible solvent ether, chloroform, di- chloromethane, ethyl acetate, etc.
  • the product is specifically beneficial for symptoms of the mucosa (oral and genital) induced by herpes simplex virus. Applied in the early stage the development of erythema and edema is suppressed and recovery is accelerated. In recurrent cases, applied before the development of symptoms, superinfection is fully inhi- bited. Furthermore, subjective symptoms, such as itching and stretching, are alleviated, and recovery is rapid and traceless. The skin becomes refreshed and hydrated.
  • Figure 1 presents the results of the compa- rative study of the preparation of the invention (herpes gel prepared according to procedure 1) and that of the commercial control products, together with the duration of recovery of untreated cases. The following control preparations were tested in the study ( Figure 1 shows the mean values of the results obtained) :
  • Medicinal gel and paint formulation containing the extract of 15 % (w/w) Chelidonium herba, 3 % (w/w) Menthae piperita folium, 1 % (w/w) Calendula officinalis, 2 % (w/w) Thy i herba and 2 % (w/w) Millefolii herba, prepared with 50 % (w/w) ethanol.
  • Medicinal suspension ointment formulation containing 0.8 % (w/w) of 3-(2-deoxy-D-ribofuranosyl)-5- isopropyluracyl.
  • Medicinal alcoholic gel formulation containing 0.2 % (w/w) primicium sulfuricum and 2 % (w/w) lidocain.
  • formulations of the preparations according to the invention are listed as follows: in the major part of indications the most advantageous formulation proved to be the rapidly absorbing and penetrating gel form which is easy to handle.
  • the formulations specified (1-3) are partly usual gels and partly microemulsions [values in the table are expressed in % by weight (w/w) ] :
  • Acrylic acid/Na acrylate copolymer (Hostacerin PN 73) 2.0 1.5 POE(45) hydrogenated ricinol acid triglyceride
  • PCL liquid Isooctadecyl isononanoate (PCL liquid) 2.0 0.3
  • Thyme- oil 0.02 0.025 0.02 Distilled water ad 100 100 100
  • the gels are prepared by dissolving allantoin in the bulk of water, then in some cases (formulations l- 2) also the copolimer, using slow stirring.
  • Ointment is also a formulation of choice, see formulations 4 to 6 [values in the table are expressed in % by weight (w/w) ] :
  • Ointments are prepared by melting the lipid components and the emulsifier - liquid paraffin, stearin, isooctyl stearate or polyoxyethylene (POE) fatty acid ester, resp. - and heating the mixture to about 70°C. Thereafter the polydocanol is added, and, if desired (formulations 5 and 6) , Irgasan. Allantoin is dissolved in water then the aqueous phase is heated to about 70°C.
  • POE polyoxyethylene
  • Alcoholic paint, drop or spray are also formulations of choice.
  • the composition of formulations 7 to 9 are listed in the following.
  • Triclosan (Irgasan OP 300) 0.05 0.1
  • the solutions are prepared by solubilizing first the thyme oil, preferably with POE(45) hydrogenated ricinol acid triglyceride. Irgasan is dissolved in alcohol, and allantoin in the bulk of water. The phases prepared in this way are mixed, then, under constant stirring the solution of ⁇ -bisabolol and collagen (formulations 7 and 8) is added to the system, finally the propyleneglycol solution of glycyrrhizin and rosemary acid. Stirring is continued for a couple of minutes after the addition.
  • Alcoholic painting composition and aerosol foam or spray composition using an appropriate carrier gas can be also prepared.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne de nouvelles compositions cosmétiques et/ou médicinales qui ont un effet bénéfique sur les infections et les inflammations virales de la peau et des muqueuses et favorisent la régénération des dermatoses causées, c'est-à-dire que les compositions permettent de rétablir l'état initial de la peau.
PCT/HU1993/000038 1992-06-18 1993-06-17 Compositions pour le traitement et la prophylaxie d'inflammations et de dermatoses induites par des virus, et procede pour leur preparation WO1993025209A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43525/93A AU4352593A (en) 1992-06-18 1993-06-17 Compositions for the treatment and prophylaxis of inflammations and dermatoses induced by viruses and process for the preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP9202040 1992-06-18
HU9202040A HU209370B (en) 1992-06-18 1992-06-18 Preparatives for treatment and preventing inflammations and other damages of skin caused by bacteria, viruses or reactive free radicals of oxygen, as well as method for making said preparatives

Publications (1)

Publication Number Publication Date
WO1993025209A1 true WO1993025209A1 (fr) 1993-12-23

Family

ID=10982077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU1993/000038 WO1993025209A1 (fr) 1992-06-18 1993-06-17 Compositions pour le traitement et la prophylaxie d'inflammations et de dermatoses induites par des virus, et procede pour leur preparation

Country Status (3)

Country Link
AU (1) AU4352593A (fr)
HU (1) HU209370B (fr)
WO (1) WO1993025209A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2287405A (en) * 1994-03-17 1995-09-20 Fischer Pharma Ltd Skin whitening compositions containing glycyrrhiza extracts
US5500448A (en) * 1993-05-13 1996-03-19 Chesebrough-Pond's Usa Co., Division Of Conopoco, Inc. Recurrent aphthous ulcer treatment method
WO1998004276A1 (fr) * 1996-07-30 1998-02-05 L'oreal Utilisation dans une composition d'un extrait d'au moins une labiee
US5945089A (en) * 1998-11-05 1999-08-31 I-Dent International Corporation Method of treating mucositis
EP0992238A1 (fr) * 1998-10-06 2000-04-12 I-Dent International Corporation Utilisation de triclosan pour la prevention et le traitement d'etats dermatologiques et muqueuses
US6440395B1 (en) 1992-06-22 2002-08-27 Barry M. Libin Antiplaque mouth rinse
WO2003045349A2 (fr) * 2001-11-27 2003-06-05 Beiersdorf Ag Preparations cosmetiques et dermatologiques pour apaiser les demangeaisons
WO2004075854A2 (fr) * 2003-02-26 2004-09-10 Program For Appropriate Technology In Health Compositions microbicides et leur mode d'emploi
FR2867947A1 (fr) * 2004-03-29 2005-09-30 Hightech Bio Activities Holdin Complexe vegetal biodecontaminant presentant a la fois des proprietes bactericides, fongicides et virucides pour le traitement de l'eau
WO2007110356A1 (fr) * 2006-03-24 2007-10-04 Istituto Farmacoterapico Italiano S.P.A. Composition de pulverisation pour usage topique pour le traitement et/ou la prevention des infections labiales a l'herpes simplex
WO2016146843A1 (fr) * 2015-03-18 2016-09-22 Bionoox Suisse Sa Compositions comprenant la dihydroquercétine pour une utilisation dans des méthodes de traitement de l'herpès
EP3000475A4 (fr) * 2013-05-23 2017-01-11 Kledos Cell Tech, S.L. Composition pharmaceutique ou cosmétique pour la régénération et la cicatrisation de la peau
CN107982521A (zh) * 2017-12-13 2018-05-04 罗强 一种女性清洁剂及制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2071494A (en) * 1980-03-08 1981-09-23 Maruzen Kasei Co Ltd Cosmetics containing 18-glycyrrhizins
JPS5913716A (ja) * 1982-07-16 1984-01-24 Lion Corp 外用組成物
GB2167296A (en) * 1982-03-05 1986-05-29 Yissum Res Dev Co Topical pharmaceutical compositions containing glycyrrhizin
JPS63188628A (ja) * 1987-01-30 1988-08-04 Shiseido Co Ltd 皮膚外用剤
FR2614787A1 (fr) * 1987-05-07 1988-11-10 Pola Kasei Kogyo Kk Cosmetique pour la peau
JPH03236323A (ja) * 1990-02-13 1991-10-22 Kobayashi Kose Co Ltd 美白用皮膚外用剤
JPH0436215A (ja) * 1990-05-29 1992-02-06 Sunstar Inc 日焼けに対する消炎性を有する化粧料
EP0487404A1 (fr) * 1990-11-19 1992-05-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Composition dermatologique externe

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2071494A (en) * 1980-03-08 1981-09-23 Maruzen Kasei Co Ltd Cosmetics containing 18-glycyrrhizins
GB2167296A (en) * 1982-03-05 1986-05-29 Yissum Res Dev Co Topical pharmaceutical compositions containing glycyrrhizin
JPS5913716A (ja) * 1982-07-16 1984-01-24 Lion Corp 外用組成物
JPS63188628A (ja) * 1987-01-30 1988-08-04 Shiseido Co Ltd 皮膚外用剤
FR2614787A1 (fr) * 1987-05-07 1988-11-10 Pola Kasei Kogyo Kk Cosmetique pour la peau
JPH03236323A (ja) * 1990-02-13 1991-10-22 Kobayashi Kose Co Ltd 美白用皮膚外用剤
JPH0436215A (ja) * 1990-05-29 1992-02-06 Sunstar Inc 日焼けに対する消炎性を有する化粧料
EP0487404A1 (fr) * 1990-11-19 1992-05-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Composition dermatologique externe

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN, Section C, Volume 12, No. 467, issued 07 December 1988, page 120, C-550; & JP,A,63 188 628, (SHISEIDO CO.). *
PATENT ABSTRACTS OF JAPAN, Section C, Volume 16, No. 20, issued 20 January 1992, page 17, C-902; & JP,A,03 236 323, (KOBAYASHI KOSE CO LTD). *
PATENT ABSTRACTS OF JAPAN, Section C, Volume 16, No. 207, issued 18 May 1992, page 23, C-941; & JP,A,04 036 215, (SUNSTAR INC). *
PATENT ABSTRACTS OF JAPAN, Section C, Volume 8, No. 98, issued 09 May 1984, page 101, C-221; & JP,A,59 013 716. *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440395B1 (en) 1992-06-22 2002-08-27 Barry M. Libin Antiplaque mouth rinse
US5500448A (en) * 1993-05-13 1996-03-19 Chesebrough-Pond's Usa Co., Division Of Conopoco, Inc. Recurrent aphthous ulcer treatment method
GB2287405A (en) * 1994-03-17 1995-09-20 Fischer Pharma Ltd Skin whitening compositions containing glycyrrhiza extracts
GB2287405B (en) * 1994-03-17 1998-08-12 Fischer Pharma Ltd Skin whitening compositions comprising glycyrrhiza extracts
WO1998004276A1 (fr) * 1996-07-30 1998-02-05 L'oreal Utilisation dans une composition d'un extrait d'au moins une labiee
FR2751878A1 (fr) * 1996-07-30 1998-02-06 Oreal Utilisation dans une composition d'un extrait d'au moins une labiee
US6060061A (en) * 1996-07-30 2000-05-09 Societe L'oreal S.A. Method for preventing or treating disorders involving an inflammatory process
EP0992238A1 (fr) * 1998-10-06 2000-04-12 I-Dent International Corporation Utilisation de triclosan pour la prevention et le traitement d'etats dermatologiques et muqueuses
US5945089A (en) * 1998-11-05 1999-08-31 I-Dent International Corporation Method of treating mucositis
WO2003045349A3 (fr) * 2001-11-27 2003-09-18 Beiersdorf Ag Preparations cosmetiques et dermatologiques pour apaiser les demangeaisons
WO2003045349A2 (fr) * 2001-11-27 2003-06-05 Beiersdorf Ag Preparations cosmetiques et dermatologiques pour apaiser les demangeaisons
WO2004075854A2 (fr) * 2003-02-26 2004-09-10 Program For Appropriate Technology In Health Compositions microbicides et leur mode d'emploi
WO2004075854A3 (fr) * 2003-02-26 2005-10-27 Program For Appropriate Techno Compositions microbicides et leur mode d'emploi
FR2867947A1 (fr) * 2004-03-29 2005-09-30 Hightech Bio Activities Holdin Complexe vegetal biodecontaminant presentant a la fois des proprietes bactericides, fongicides et virucides pour le traitement de l'eau
WO2007110356A1 (fr) * 2006-03-24 2007-10-04 Istituto Farmacoterapico Italiano S.P.A. Composition de pulverisation pour usage topique pour le traitement et/ou la prevention des infections labiales a l'herpes simplex
JP2009530350A (ja) * 2006-03-24 2009-08-27 イスチチュト ファルマコテラピコ イタリアーノ ソシエタ ペル アチオニ 口唇単純ヘルペス感染症の治療および／または予防のための局所使用用スプレー組成物
EP3000475A4 (fr) * 2013-05-23 2017-01-11 Kledos Cell Tech, S.L. Composition pharmaceutique ou cosmétique pour la régénération et la cicatrisation de la peau
WO2016146843A1 (fr) * 2015-03-18 2016-09-22 Bionoox Suisse Sa Compositions comprenant la dihydroquercétine pour une utilisation dans des méthodes de traitement de l'herpès
US11077087B2 (en) 2015-03-18 2021-08-03 Bionoox Suisse Sa Compositions comprising dihydroquercetin for use in methods for treating herpes
CN107982521A (zh) * 2017-12-13 2018-05-04 罗强 一种女性清洁剂及制备方法

Also Published As

Publication number Publication date
HU9202040D0 (en) 1992-09-28
AU4352593A (en) 1994-01-04
HU209370B (en) 1994-05-30

Similar Documents

Publication Publication Date Title
US4382886A (en) Method for extracting propolis and water soluble dry propolis powder
WO2011126539A2 (fr) Compositions et méthodes de traitement de peau de mammifères
HU202743B (en) Active ingredient composition comprising medicinal herb extracts, cosmetics comprising such active ingredient and process for producing medicinal and veterinary compositions
WO1993025209A1 (fr) Compositions pour le traitement et la prophylaxie d'inflammations et de dermatoses induites par des virus, et procede pour leur preparation
GB2459121A (en) A product for topical administration
EP0109993B1 (fr) Méthode d'extraction de la propolis, poudre sèche de propolis soluble dans l'eau ainsi obtenue et préparations cosmétiques et pharmaceutiques la contenant
KR20170103172A (ko) 병풀추출물, 세라마이드 및 자작나무수액을 포함하는 피부 자극 완화 및 피부 장벽 개선 효과의 화장료 조성물
US20010033849A1 (en) Cosmetic compositions having retarding action on the regrowth of superfluous hair
KR20000049163A (ko) 식물엑기스를 함유하는 의약 내지 화장품의 여드름치료제조성물
CN111184751A (zh) 一种含细梗香草外用制剂及其应用
KR100530843B1 (ko) 동충하초 추출물을 유효성분으로 포함하는 항염 조성물
CN110200888A (zh) 一种无香精的植物护肤面膜及其制备方法
CN106491634B (zh) 玻璃酸二甲基硅烷醇复合物及其组合物
CN112870140A (zh) 一种抗敏止痒组合物、护肤凝露及其制备方法、应用
JPS5913716A (ja) 外用組成物
EP0348215B1 (fr) Compositions cosmétiques et paramédicinales
KR102481125B1 (ko) 며느리배꼽 추출물을 포함하는 피부 안티폴루션용 조성물
KR100754748B1 (ko) 느릅 추출물을 유효성분으로 함유하는 ５α-리덕테이즈활성 억제용 조성물 및 피지 분비 억제용 화장료 조성물
JP2894715B2 (ja) 皮膚外用剤
CN106074258B (zh) 一种消炎止痒洁肤按摩冻
KR20210024268A (ko) 병풀추출물, 세라마이드 및 자작나무수액을 포함하는 피부 자극 완화 및 피부 장벽 개선 효과의 화장료 조성물
CN110151657A (zh) 一种含有垂盆草提取物的祛痘凝胶及其制备方法
JP2007084448A (ja) ヒアルロン酸産生促進剤および皮膚外用剤
KR102765121B1 (ko) 식물 캘러스를 포함하는 스크럽 조성물
CN101703754B (zh) 一种治疗白脉病的鼻用制剂及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB JP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: BY

121 Ep: the epo has been informed by wipo that ep was designated in this application
EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Ref country code: BY

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Ref country code: UZ

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: UZ

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: BY

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: BY

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载